Cargando…

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series

OBJECTIVE: To evaluate the efficacy and safety of half-fluence photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC) in Omani population. MATERIALS AND METHODS: A Retrospective chart review of all patients with chronic CSC treated with half-fluence PDT from November 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Hinai, Ahmed S., Al-Abri, Mohammed S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160071/ https://www.ncbi.nlm.nih.gov/pubmed/21897620 http://dx.doi.org/10.4103/0974-620X.83655

Ejemplares similares

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy
por: Ma, Dae Joong, et al.
Publicado: (2018)

Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy
por: Stattin, Martin, et al.
Publicado: (2020)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Naseripour, Masood, et al.
Publicado: (2016)

Aniseikonia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy
por: Chubachi-Kamimura, Aya, et al.
Publicado: (2023)

Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic Therapy
por: Yanık, Özge, et al.
Publicado: (2022)

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
por: Ratanasukon, Mansing, et al.
Publicado: (2013)

Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy
por: Hayashida, Mayuka, et al.
Publicado: (2020)

Effectiveness of Reduced-fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Propensity Score Analysis
por: Aisu, Nao, et al.
Publicado: (2022)

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
por: Fujita, Kyoko, et al.
Publicado: (2012)

Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
por: Alovisi, Camilla, et al.
Publicado: (2020)

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
por: Servillo, Andrea, et al.
Publicado: (2023)

A Comparative Study of Short-Term Vascular and Stromal Alterations of the Choroid Following Half-Fluence Photodynamic Therapy in Pachychoroid Neovasculopathy and Chronic Central Serous Chorioretinopathy
por: Yanık, Özge, et al.
Publicado: (2022)

Low-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the Treatment of Chronic Central Serous Chorioretinopathy
por: Özmert, Emin, et al.
Publicado: (2016)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
por: Atik, Alp, et al.
Publicado: (2017)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Kinoshita, Takamasa, et al.
Publicado: (2016)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy
por: Cidad, Pino, et al.
Publicado: (2015)

Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
por: Horiguchi, Etsuyo, et al.
Publicado: (2022)

Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy
por: Iwase, Takehito, et al.
Publicado: (2020)

Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report
por: Zhang, Zhengwei, et al.
Publicado: (2021)

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization
por: Kamimura, Aya, et al.
Publicado: (2023)

Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity
por: Hayashida, Mayuka, et al.
Publicado: (2020)

Real world outcomes of photodynamic therapy for chronic central serous chorioretinopathy
por: Khandhadia, Samir, et al.
Publicado: (2022)

The comparison of multimodal imaging findings of central serous chorioretinopathy patients in regard to the early anatomically treatment response to half-fluence photodynamic therapy: a retrospective case–control study
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Nassisi, Marco, et al.
Publicado: (2017)

Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
por: Zeng, Miao, et al.
Publicado: (2022)

Three-Year Follow-Up Detecting Choroidal Neovascularization with Swept Source Optical Coherence Tomography Angiography (SS-OCTA) after Successful Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Esteban-Floría, Olivia, et al.
Publicado: (2023)

Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy
por: Tsakonas, George D, et al.
Publicado: (2012)

Anatomical Retinal Changes after Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
por: Ruiz-del-Tiempo, María Pilar, et al.
Publicado: (2018)

Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea
por: van Dijk, Elon H. C., et al.
Publicado: (2017)

Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy
por: Mohabati, Danial, et al.
Publicado: (2018)

Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Noh, Sung Rae, et al.
Publicado: (2019)

One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy
por: Pichai, Jirarattanasopa, et al.
Publicado: (2021)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lll9c3kgosm15fc0m12jdreqtf